Esmolol for tight heart rate control in patients with STEMI: Design and rationale of the beta-blocker in acute myocardial infarction (BEAT-AMI) trial

International Journal of Cardiology

Volumn 190, Issue , 2015, Pages 351-352

  Er, Fikret ^a   Erdmann, Erland ^b   Nia, Amir M ^c   Dahlem, Kristina M ^b   Biesenbach, Esther ^b   Herrfurth, Tina ^b   Taghiyev, Zulfugar ^b   Le, Minh Tam ^b   Hellmich, Martin ^b   Kuhr, Kathrin ^b   Caglayan, Evren ^b   Gassanov, Natig ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Beta blocker; Esmolol; Heart rate control; STEMI

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; ESMOLOL; PLACEBO; TROPONIN T; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROPANOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EMOTIONAL STRESS; HEART INFARCTION SIZE; HEART INJURY; HEART PROTECTION; HEART RATE; HEART RATE CONTROL; HUMAN; LETTER; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPATHETIC TONE; DRUG EFFECTS; METHODOLOGY; MYOCARDIAL INFARCTION; PROCEDURES;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; HEART RATE; HUMANS; MYOCARDIAL INFARCTION; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84930680016     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.177     Document Type: Article

References (10)

1. N. Freemantle, J. Cleland, and P. Young beta Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
2. Task Force on the management of STseamiotESoC, P.G. Steg, and S.K. James ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J. 33 2012 2569 2619
3. A. Hjalmarson, D. Elmfeldt, and J. Herlitz Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial Lancet 2 1981 823 827
4. S. Yusuf, D. Ramsdale, and R. Peto Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial Lancet 2 1980 273 276
5. Z.M. Chen, H.C. Pan, and Y.P. Chen Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1622 1632
6. A. Halkin, C.L. Grines, and D.A. Cox Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction J. Am. Coll. Cardiol. 43 2004 1780 1787
7. K.J. Harjai, G.W. Stone, and J. Boura Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction Am. J. Cardiol. 91 2003 655 660
8. B. Ibanez, C. Macaya, and V. Sanchez-Brunete Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial Circulation 128 2013 1495 1503
9. R.A. Little, K.N. Frayn, and P.E. Randall Plasma catecholamines in the acute phase of the response to myocardial infarction Arch. Emerg. Med. 3 1986 20 27
10. J. Schulze, A. Vogelgesang, and A. Dressel Catecholamines, steroids and immune alterations in ischemic stroke and other acute diseases Aging Dis. 5 2014 327 339